MARKET

PRNAF

PRNAF

Alterity Therapeutics Ltd
OTCPK
0.400
NaN%
Closed 09:30 10/05 EDT
OPEN
--
PREV CLOSE
0.400
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.540
52 WEEK LOW
0.010
MARKET CAP
91.66M
P/E (TTM)
-5.2016
1D
5D
1M
3M
1Y
5Y
1D
Alterity’s ATH434 slowed multiple system atrophy decline 52% in new data
TipRanks · 10h ago
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
Barchart · 17h ago
Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial
TipRanks · 1d ago
Alterity Flags Development Risks Around Lead Neurodegeneration Drug ATH434
TipRanks · 09/23 00:09
Parties in the Matter of Athene Holding Ltd v Imran Siddiqui Announce Settlement
Barchart · 09/18 07:30
Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference
TipRanks · 09/17 23:48
Alterity Therapeutics Seeks Quotation for New ASX Shares
TipRanks · 09/16 02:43
Alterity Therapeutics management to meet virtually with Lake Street
TipRanks · 09/15 13:45
More
About PRNAF
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Webull offers Alterity Therapeutics Ltd stock information, including OTCPK: PRNAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRNAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRNAF stock methods without spending real money on the virtual paper trading platform.